S&P 500   3,326.80 (+0.18%)
DOW   29,190.82 (-0.02%)
QQQ   224.59 (+0.59%)
AAPL   318.76 (+0.69%)
FB   222.12 (+0.31%)
MSFT   165.99 (-0.31%)
GOOGL   1,491.79 (+0.64%)
AMZN   1,893.00 (+0.05%)
NVDA   251.94 (+1.61%)
MU   59.62 (+1.10%)
GE   11.36 (-2.57%)
TSLA   587.41 (+7.35%)
AMD   51.59 (+1.06%)
T   39.05 (+1.38%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   330.49 (-2.25%)
BAC   34.25 (-0.03%)
DIS   144.01 (+0.31%)
GILD   63.08 (+0.72%)
S&P 500   3,326.80 (+0.18%)
DOW   29,190.82 (-0.02%)
QQQ   224.59 (+0.59%)
AAPL   318.76 (+0.69%)
FB   222.12 (+0.31%)
MSFT   165.99 (-0.31%)
GOOGL   1,491.79 (+0.64%)
AMZN   1,893.00 (+0.05%)
NVDA   251.94 (+1.61%)
MU   59.62 (+1.10%)
GE   11.36 (-2.57%)
TSLA   587.41 (+7.35%)
AMD   51.59 (+1.06%)
T   39.05 (+1.38%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   330.49 (-2.25%)
BAC   34.25 (-0.03%)
DIS   144.01 (+0.31%)
GILD   63.08 (+0.72%)
S&P 500   3,326.80 (+0.18%)
DOW   29,190.82 (-0.02%)
QQQ   224.59 (+0.59%)
AAPL   318.76 (+0.69%)
FB   222.12 (+0.31%)
MSFT   165.99 (-0.31%)
GOOGL   1,491.79 (+0.64%)
AMZN   1,893.00 (+0.05%)
NVDA   251.94 (+1.61%)
MU   59.62 (+1.10%)
GE   11.36 (-2.57%)
TSLA   587.41 (+7.35%)
AMD   51.59 (+1.06%)
T   39.05 (+1.38%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   330.49 (-2.25%)
BAC   34.25 (-0.03%)
DIS   144.01 (+0.31%)
GILD   63.08 (+0.72%)
S&P 500   3,326.80 (+0.18%)
DOW   29,190.82 (-0.02%)
QQQ   224.59 (+0.59%)
AAPL   318.76 (+0.69%)
FB   222.12 (+0.31%)
MSFT   165.99 (-0.31%)
GOOGL   1,491.79 (+0.64%)
AMZN   1,893.00 (+0.05%)
NVDA   251.94 (+1.61%)
MU   59.62 (+1.10%)
GE   11.36 (-2.57%)
TSLA   587.41 (+7.35%)
AMD   51.59 (+1.06%)
T   39.05 (+1.38%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   330.49 (-2.25%)
BAC   34.25 (-0.03%)
DIS   144.01 (+0.31%)
GILD   63.08 (+0.72%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Aratana Therapeutics Price Target & Analyst Ratings (NASDAQ:PETX)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$4.92
0.00 (0.00 %)
(As of 07/18/2019)
Add
Compare
Today's Range
$4.92
Now: $4.92▼
$4.92
50-Day Range
$4.92
MA: $4.92▼
$4.92
52-Week Range
$3.30
Now: $4.92▼
$7.16
VolumeN/A
Average Volume1.03 million shs
Market Capitalization$241.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4

Analyst Ratings

Aratana Therapeutics (NASDAQ:PETX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Aratana Therapeutics in the last 12 months. Their average twelve-month price target is $4.63, suggesting that the stock has a possible downside of 5.83%. The high price target for PETX is $5.00 and the low price target for PETX is $4.14. There are currently 3 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.63$4.73$4.73$4.73
Price Target Upside: 5.83% downside0.74% downside0.74% downside0.74% downside

Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$4.76Low
4/26/2019HC WainwrightDowngradeBuy ➝ Neutral$5.00High
1/24/2019William BlairDowngradeOutperform ➝ Market Perform$4.14Medium
1/11/2019Stifel NicolausDowngradeBuy ➝ Hold$8.00 ➝ $5.00High
3/12/2018CL KingUpgradeNeutral ➝ Buy$8.00High
(Data available from 1/22/2018 forward)
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: What is the definition of a trade war?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel